

# 2017 White Paper on recent issues in bioanalysis: a global guidelines & biomarker assay performance (Part 3)

Bioanalysis

9, 1967-1996

DOI: [10.4155/bio-2017-4974](https://doi.org/10.4155/bio-2017-4974)

Citation Report

#	ARTICLE	IF	CITATIONS
1	2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part 1) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	32
2	Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. Bioanalysis, 2018, 10, 803-814.	0.6	17
3	Biomarker assays: is it time for a standalone regulatory guidance?. Bioanalysis, 2018, 10, 1893-1895.	0.6	3
5	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 " PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq1 1 0 0 784314 rgBT /Overlock 10	0.6	18
6	2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 " LBA/cell-based assays: immunogenicity, biomarkers and PK) Tj ETQq0 0 0 rgBT /Overlock 10 TF 5	0.6	10
7	Biomarker assay validation. Bioanalysis, 2018, 10, 889-891.	0.6	14
8	12th GCC Closed Forum: critical reagents; oligonucleotides; CoA; method transfer; HRMS; flow cytometry; regulatory findings; stability and immunogenicity. Bioanalysis, 2019, 11, 1129-1138.	0.6	9
9	Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC-MS. Bioanalysis, 2019, 11, 785-795.	0.6	13
10	Harmonization and standardization of immunogenicity assessment of biotherapeutic products. Bioanalysis, 2019, 11, 1593-1604.	0.6	8
11	Compatibility of immunogenicity guidance by the EMA and the US FDA. Bioanalysis, 2019, 11, 1619-1629.	0.6	9
12	Looking beyond the WRIB Decennial Index of the White Papers in Bioanalysis. Bioanalysis, 2019, 11, 563-565.	0.6	1
13	Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis. Bioanalysis, 2019, 11, 645-653.	0.6	9
14	Celebrating 10 years of publishing <i>Bioanalysis</i>. Bioanalysis, 2019, 11, 551-553.	0.6	1
15	Analysis of regulatory guidance on antidrug antibody testing for therapeutic protein products. Bioanalysis, 2019, 11, 2283-2296.	0.6	6
16	2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (Part 1 " Innovation in Small) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	24
18	2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (<u>Part 2</u> " Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV) Tj ETQq1 1 0 0 784314 rgBT /Overlock 10	0.6	18
19	Review of Recommendations for Bioanalytical Method Validation: Chromatographic Assays and Ligand Binding Assays. Chromatographia, 2019, 82, 523-535.	0.7	1
20	Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?. Bioanalysis, 2020, 12, 1325-1336.	0.6	7

#	ARTICLE	IF	CITATIONS
21	Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody reagent complexes at cut-point (CP-ARC) the missing piece?. <i>Bioanalysis</i> , 2020, 12, 1021-1031.	0.6	8
22	2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome (<u>Part 1</u> â€“ Recommendations) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6	0.6	24
23	2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (<u>Part 3</u> â€“) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.6	31
24	2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory FeedbackA (<u>Part 2A</u> â€“ Recommendations on) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6	0.6	16
25	Development of a Meso Scale Discovery ligand-binding assay for measurement of free (drug-unbound) target in nonhuman primate serum. <i>Bioanalysis</i> , 2021, 13, 575-585.	0.6	1
26	The impact of ligand binding based assays critical reagent characterization and storage. <i>Bioanalysis</i> , 2021, 13, 797-805.	0.6	3
27	Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 674747.	1.6	27
28	Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration. <i>Frontiers in Veterinary Science</i> , 2021, 8, 687448.	0.9	3
29	14-Year Changes in Plasma Neurofilament Levels Among Men: A Pilot Study. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 621-624.	1.1	0
30	An Integrated Analysis of Dostarlimab Immunogenicity. <i>AAPS Journal</i> , 2021, 23, 96.	2.2	10
31	An Alternative Data Transformation Approach for ADA Cut Point Determination: Why Not Use a Weibull Transformation?. <i>AAPS Journal</i> , 2021, 23, 97.	2.2	2
32	Towards a more patient-centric assessment of immunogenicity for low-risk biologics in immuno-oncology clinical trials. <i>Bioanalysis</i> , 2021, 13, 1309-1312.	0.6	1
33	Critical reagents for ligand-binding assays: process development methodologies to enable high-quality reagents. <i>Bioanalysis</i> , 2022, 14, 117-135.	0.6	1
34	Assay pH and critical reagent optimization in measuring concentrations of a monoclonal antibody and its target. <i>Bioanalysis</i> , 2022, , .	0.6	0
35	A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody. <i>AAPS Open</i> , 2021, 7, .	0.4	2
36	Biomarker Assay Validation by Mass Spectrometry. <i>AAPS Journal</i> , 2022, 24, 66.	2.2	6
37	2021 White Paper on Recent Issues in Bioanalysis: ISR for Biomarkers, Liquid Biopsies, Spectral Cytometry, Inhalation/Oral & Multispecific Biotherapeutics, Accuracy/LLOQ for Flow Cytometry (<u>Part 2</u> â€“ Recommendations on Biomarkers/CDx Assays Development & Validation,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.6	14
38	2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CDSPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory InputsA (<u>Part 1A</u> â€“ Recommendations on Endogenous Compounds, Small Molecules,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6	0.6	14

#	ARTICLE	IF	CITATIONS
39	2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness (Part 3) Recommendations on Gene Therapy, Tj ETQq 0.0 0 rgBT1/Overlock	0.6	1
40	Novel isoelectric target depletion (ITaD) protocol reduces the need for specific reagents for immunogenicity testing. Bioanalysis, 2022, 14, 725-735.	0.6	1
42	Direct bioanalysis or indirect calculation of target engagement and free drug exposure: do we apply double standards?. Bioanalysis, 2023, 15, 5-16.	0.6	2